MediWound Ltd - Company Profile
Powered by 
All the data and insights you need on MediWound Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date MediWound Ltd Strategy Report
- Understand MediWound Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MediWound Ltd (MediWound) is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in Europe and Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
Headquarters
Israel
Address
42 Hayarkon Street, Yavne, 8122745
Website
www.mediwound.com
Telephone
972 8 9324010
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MDWD (NASD)
Revenue (2022)
$18.7M
-29.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
65.7%
(2022 vs 2021)
Market Cap*
$179.9M
Net Profit Margin (2022)
XYZ
51.4%
(2022 vs 2021)
* As of and is in US$
MediWound Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| NexoBrid - Debridement | EscharEx |
| Pipeline: | NexoBrid |
| NexoBrid - Severe Burns | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with 3M Health Care to provide its two-layer compression systems Coban 2 and Coban 2 Lite. |
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with Molnlycke for its upcoming Phase III study of EscharEx in venous leg ulcers (VLUs). |
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with MIMEDX Group, Inc. on EscharEx Phase III Study. |
Competitor Comparison
| Key Parameters | MediWound Ltd | Smith & Nephew Plc | RedHill Biopharma Ltd | Oramed Pharmaceuticals Inc | Endo Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Israel | United Kingdom | Israel | United States of America | United States of America |
| City | Yavne | Watford | Tel Aviv-Yafo | New York | Chester |
| State/Province | - | England | - | New York | Pennsylvania |
| No. of Employees | 100 | 18,452 | 53 | 15 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nachum Shamir | Chairman; Director | Executive Board | 2023 | 68 |
| Ofer Gonen | Director; Chief Executive Officer | Executive Board | 2022 | 50 |
| Hani Luxenburg | Chief Financial Officer | Senior Management | 2023 | - |
| Tzvi Palash | Chief Operating Officer | Senior Management | 2022 | 67 |
| Shmulik Hess, Ph.D | Chief Commercial Officer; Chief Operating Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer